Ignite Creation Date:
2024-05-06 @ 7:08 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05908721
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-06-18
First Post:
2023-06-08
Brief Title:
Study of CM310 in Patients With Allergic Rhinitis
Sponsor:
Keymed Biosciences CoLtd
Organization:
Keymed Biosciences CoLtd
Study Overview
Official Title:
A Multicenter Single Arm Phase II Clinical Study Evaluating the Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Seasonal Allergic Rhinitis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter single arm open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis
Detailed Description:
Allergic rhinitis AR is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E IgE in atopic individuals exposed to allergens
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None